期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 94, 期 3, 页码 336-348出版社
WILEY
DOI: 10.1038/clpt.2013.115
关键词
-
资金
- Agency for Healthcare Research and Quality [K08HS18465-01]
- Robert Wood Johnson Foundation
Some observers of drug development argue that the pace of pharmaceutical innovation is declining, but others deny that contention. This controversy may be due to different methods of defining and assessing innovation. We conducted a systematic review of the literature to develop a taxonomy of methods for measuring innovation in drug development. The 42 studies fell into four main categories: counts of new drugs approved, assessments of therapeutic value, economic outcomes, and patents issued. The definition determined whether a study found a positive or negative trend in innovative drug development. Of 21 studies that relied on counts, 9(43%) concluded that the trend for drug discovery was favorable, 11(52%) concluded that the trend was not favorable, and 1 reached no conclusion. By contrast, of 21 studies that used other measures of innovation, 0 concluded that the trend was favorable, 8(47%) concluded that the trend was not favorable, and 13 reached no conclusion (P = 0.03).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据